Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome
Yıl: 2019 Cilt: 51 Sayı: 3 Sayfa Aralığı: 280 - 284 Metin Dili: İngilizce DOI: 10.5152/eurasianjmed.2019.18420 İndeks Tarihi: 24-04-2020
Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome
Öz: Metabolic syndrome is associated with a group of conditions abdominal obesity, high triglyceride levels, reduction in low-density lipoprotein, increased blood pressure, and increased fasting blood glucose. Hence, it poses a risk for type 2 diabetes and cardiovascular diseases. The prevalence of metabolic syndrome increases with age. Nesfatin-1, which affects different systems, has recently been discovered as a regulatory peptide molecule. With the discovery of nesfatin-1, it has been reported to inhibit the intake of nutrients and have significant regulatory effects on energy metabolism. As nesfatin-1 is present in both central and peripheral tissues, it is thought to have many functions. In addition to its suppressive effect on food intake, nesfatin-1 has also been reported to have an effect on the blood glucose level for regulating cardiac functions and affecting obesity by providing weight loss. Considering the effects of nesfatin-1, it may be associated with metabolic syndrome.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1. Koç F, Tokaç M, Kocabaş V, et al. Ghrelin, Resistin and Leptin Levels in Patients with Metabolic Syndrome. Eur J Gen Med 2011; 8: 92-7. [CrossRef]
- 2. Kim SR, Lehman LO. Diagnostic imaging in the management of patients with metabolic syndrome. Transl Res 2018; 194: 1-18. [CrossRef]
- 3. Turkish Endocrinology and Metabolism Association, The Metabolic Syndrome Guide, 2009 (in Turkish). Date of Access: 12.03.2018
- 4. Mirzaei K, Nezhad AH, Keshavarz SA, et al. Crosstalk between circulating peroxisome proliferator-activated receptor gamma, adipokines and metabolic syndrome in obese subjects. Diabetol Metab Syndr 2013; 5: 79. [CrossRef]
- 5. Abaci A, Catli G, Anik A, Kume T, Bober E. The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children. Pediatr Diabetes 2013; 14: 189-95. [CrossRef]
- 6. Algül S, Özçelik O. Determination of the Effects of Acute Aerobic Exercise on Nesfatin-1 Levels. Fırat University Medical Journal of Health Sciences. 2016; 30: 5-8.
- 7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9. [CrossRef]
- 8. Alexander CA. The coming of age of the metabolic syndrome. Diabetes Care 2003; 26: 3180-1. [CrossRef]
- 9. Altuntaş Y. Metabolic syndrome and insulin resistance. Metabolic Syndrome Yearbook. Metabolic Syndrome Association. Ayrıntı Printing House, Ankara, 2009.
- 10. Grundy SM, Brewer Jr HB, Cleeman JI. Definition of Metabolic Syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 433-8. [CrossRef]
- 11. Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443: 709-12. [CrossRef]
- 12. Stengel A, Tache Y. Nesfatin-1--An Emerging New Player in the Brain-Gut, Endocrine, and Metabolic Axis. Endocrinology 2011; 152: 4033-8. [CrossRef]
- 13. Aydın S. Multi-functional peptide hormone NUCB2/nesfatin-1. Endocrine 2013; 44: 312-25. [CrossRef]
- 14. García-Galiano D, Navarro VM, Gaytan F, Tena-Sempere M. Expanding roles of NUCB2/nesfatin-1 in neuroendocrine regulation. J Mol Endocrinol 2010; 45: 281-90. [CrossRef]
- 15. Stengel A. Nesfatin-1 - More than a food intake regulatory peptide. Peptides 2015; 72: 175-83. [CrossRef]
- 16. Shimizu H, Oh-I S, Hashimoto K, et al. Peripheral Administration of Nesfatin-1 Reduces Food Intake in Mice: The Leptin-Independent Mechanism. Endocrinology 2009; 150: 662-71. [CrossRef]
- 17. Algül S, Özçelik O. A New Promising Pepdide for Obesity Treatment: Nesfatin-1. Fırat University Medical Journal of Health Sciences 2012; 26: 143-8.
- 18. Stengel A, Goebel M, Taché Y. Nesfatin-1: a novel inhibitory regulator of food intake and body weight. Obes Rev 2010; 12: 261-71. [CrossRef]
- 19. Prinz P, Stengel A. Nesfatin-1: current status as a peripheral hormone and future prospects. Curr Opin Pharmacol 2016; 31: 19-24. [CrossRef]
- 20. Prinz P, Stengel A. Expression and regulation of peripheral NUCB2/nesfatin-1. Curr Opin Pharmacol 2016; 31: 25-30. [CrossRef]
- 21. Algül Ş, Özkan Y, Özçelik O. Serum Nesfatin-1 Levels in Patients With Different Glucose Tolerance Levels. Physiol Res 2016; 65: 979-85.
- 22. Catak Z, Aydin S, Sahin I, Kuloglu T, Aksoy A, Dagli AF. Regulatory neuropeptides (ghrelin, obestatin and nesfatin-1) levels in serum and reEurasian productive tissues of female and male rats with fructose-induced metabolic syndrome. Neuropeptides 2014; 48: 167-77. [CrossRef]
- 23. Aksu O, Aydın B, Doguç DK, et al. The evaluation of Nesfatin-1 levels in patients with OSAS associated with metabolic syndrome. J Endocrinol Invest 2015; 38: 463-9. [CrossRef]
- 24. Zegers D, Beckers S, Mertens IL, Van Gaal LF, Van Hul W. Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. Mol Genet Metab 2011; 103: 282-6. [CrossRef]
- 25. Zegers D, Beckers S, de Freitas F, et al. Identification of mutations in the NUCB2/nesfatin gene in children with severeobesity. Mol Genet Metab 2012; 107: 729-34. [CrossRef]
- 26. Miyata S, Yamada N, Kawada T. Possible involvement of hypothalamic nucleobindin-2 in hyperphagic feeding in Tsumura Suzuki obese diabetes mice. Biol Pharm Bull 2012; 35: 1784-93. [CrossRef]
- 27. Ogiso K, Asakawa A, Amitani H, et al. Plasma nesfatin-1 concentrations in restricting-type anorexia nervosa. Peptides 2011; 32; 150-3. [CrossRef]
- 28. Zhang Z, Li L, Yang M, Liu H, Boden G, Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2012; 120: 91-5. [CrossRef]
- 29. Tan BK, Hallschmid M, Kern W, Lehnert H, Randeva HS. Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: Evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. J Clin Endocrinol Metab 2011; 96: 669-73. [CrossRef]
- 30. Yosten GLC. Novel Neuropeptides in the Control of Food intake: Neuronostatin and nesfatin-1. Vitam Horm 2013; 92: 1-25. [CrossRef]
- 31. Başar O, Akbal E, Köklü S, et al. A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease. Scand. J Clin Lab Invest 2012; 72: 479-83. [CrossRef]
- 32. Tsuchiya T, Shimizu H, Yamada M, et al. Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin Endocrinol 2010; 73: 484-90. [CrossRef]
- 33. Ramanjaneya M, Chen J, Brown JE, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010; 151: 3169-80. [CrossRef]
- 34. Stengel A, Hofmann T, Goebel-Stengel M, et al. Ghrelin and NUCB2/nesfatin-1 are expressed in the same gastric cell and differentially correlated with body mass index in obese subjects. Histochem Cell Biol 2013; 139: 909-18. [CrossRef]
- 35. Tuomilehto HPI, Seppä JM, Partinen MM, et al. Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med 2009; 179: 320-7. [CrossRef]
- 36. Saraç S, Afşar GÇ, Oruç Ö, Kırbaş G, Görgüner AM. The Relationship of Obesity and Concomitant Diseases in the Patients with Obstructive Sleep Apnea Syndrome. Van Medial Journal 2015; 22: 246-51.
- 37. Araz O, Ucar EY, Dorman E, et al. Is There a Relationship between Obstructive Sleep Apnea Syndrome Severity and Nesfatin-1? Respiration 2015; 90: 105-10. [CrossRef]
- 38. Shen P, Han Y, Cai B, Wang Y. Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome. Sleep Breath 2015; 19: 515-22. [CrossRef]
- 39. Su Y, Zhang J, Tang Y, Bi F, Liu JN. The novel function of nesfatin-1: anti-hyperglycemia. Biochem Biophys Res Commun 2010; 391: 1039-42. [CrossRef]
- 40. Li Z, Gao L, Tang H, et al. Peripheral effects of nesfatin-1 on glucose homeostasis. PLOS One 2013; 8: e71513. [CrossRef]
- 41. Gonzalez R, Perry RL, Gao X, et al. Nutrient responsive nesfatin-1 regulates energy balance and induces glucose-stimulated insulin secretion in rats. Endocrinology 2011; 152: 3628-37. [CrossRef]
- 42. Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept 2010; 159: 72-7. [CrossRef]
- 43. Aslan M, Celik O, Celik N, et al. Cord blood nesfatin-1 and apelin-36 levels in gestational diabetes mellitus. Endocrine 2012; 41: 424-9. [CrossRef]
- 44. Feijóo-Bandín S, Rodríguez-Penas D, García-Rúa V, Mosquera-Leal A, González-Juanatey JR, Lago F. Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level. Endocrine 2016; 52: 11-29. [CrossRef]
- 45. Yosten GL, Samson WK. Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol 2009; 297: 330-6. [CrossRef]
- 46. Yamawaki H, Takahashi M, Mukohda M, Morita T, Okada M, Hara Y. A novel adipocytokine, nesfatin-1 modulates peripheral arterial contractility and blood pressure in rats. Biochem Biophys Res Commun 2012; 418: 676-81. [CrossRef]
- 47. Zhao Y, Ma X, Wang Q, et al. Nesfatin-1 correlates with hypertension in overweight or obese Han Chinese population. Clin Exp Hypertens 2015; 37: 51-6. [CrossRef]
- 48. Şahin FK, Şahin SB, Ural ÜM, M. et al. Nesfatin-1 and vitamin D levels may be associated with systolic and diastolic blood pressure values and hearth rate in polycystic ovary syndrome. Bosn J Basic Med Sci 2015; 15: 57-63. [CrossRef]
- 49. Angelone T, Filice E, Pasqua T, et al. Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury. Cell Mol Life Sci 2013; 70: 495-509. [CrossRef]
- 50. Yin Y, Li Z, Gao L, Li Y, Zhao J, Zhang W. AMPK-dependent modulaion of hepatic lipid metabolism by nesfatin-1. Mol Cell Endocrinol 2015; 417: 20-6. [CrossRef]
| APA | tekin t, ÇİÇEK B, konyalıgil n (2019). Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. , 280 - 284. 10.5152/eurasianjmed.2019.18420 |
| Chicago | tekin tuba,ÇİÇEK Betül,konyalıgil nurefşan Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. (2019): 280 - 284. 10.5152/eurasianjmed.2019.18420 |
| MLA | tekin tuba,ÇİÇEK Betül,konyalıgil nurefşan Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. , 2019, ss.280 - 284. 10.5152/eurasianjmed.2019.18420 |
| AMA | tekin t,ÇİÇEK B,konyalıgil n Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. . 2019; 280 - 284. 10.5152/eurasianjmed.2019.18420 |
| Vancouver | tekin t,ÇİÇEK B,konyalıgil n Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. . 2019; 280 - 284. 10.5152/eurasianjmed.2019.18420 |
| IEEE | tekin t,ÇİÇEK B,konyalıgil n "Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome." , ss.280 - 284, 2019. 10.5152/eurasianjmed.2019.18420 |
| ISNAD | tekin, tuba vd. "Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome". (2019), 280-284. https://doi.org/10.5152/eurasianjmed.2019.18420 |
| APA | tekin t, ÇİÇEK B, konyalıgil n (2019). Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. Eurasian Journal of Medicine, 51(3), 280 - 284. 10.5152/eurasianjmed.2019.18420 |
| Chicago | tekin tuba,ÇİÇEK Betül,konyalıgil nurefşan Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. Eurasian Journal of Medicine 51, no.3 (2019): 280 - 284. 10.5152/eurasianjmed.2019.18420 |
| MLA | tekin tuba,ÇİÇEK Betül,konyalıgil nurefşan Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. Eurasian Journal of Medicine, vol.51, no.3, 2019, ss.280 - 284. 10.5152/eurasianjmed.2019.18420 |
| AMA | tekin t,ÇİÇEK B,konyalıgil n Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. Eurasian Journal of Medicine. 2019; 51(3): 280 - 284. 10.5152/eurasianjmed.2019.18420 |
| Vancouver | tekin t,ÇİÇEK B,konyalıgil n Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. Eurasian Journal of Medicine. 2019; 51(3): 280 - 284. 10.5152/eurasianjmed.2019.18420 |
| IEEE | tekin t,ÇİÇEK B,konyalıgil n "Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome." Eurasian Journal of Medicine, 51, ss.280 - 284, 2019. 10.5152/eurasianjmed.2019.18420 |
| ISNAD | tekin, tuba vd. "Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome". Eurasian Journal of Medicine 51/3 (2019), 280-284. https://doi.org/10.5152/eurasianjmed.2019.18420 |
